MetaDeq Diagnostics

Menu

Our Mission

Aid physicians to identify, diagnose, stage and monitor MASLD & MASH patients with a simple and accurate blood test

Simple Blood-Based Diagnosis of MASH
and Liver Fibrosis

The value propositions and business model include:

  • Provide an alternate / complement to liver biopsies to change clinical practice and industry guidelines
  • Enable PCPs and GPs to identify MASH patients before significant disease progression can occur
  • Monitor patient response to new medications
  • Lower costs to the Healthcare system
  • Three sources of future revenue generation:
    1. Commercialization of an accurate, blood-based diagnostic test to detect MASH
    2. Partnership(s) with CROs to reduce clinical trial screen failure rates
    3. Development of companion diagnostics

MASH: The Unmet Need

 

Obesity, Diabetes & Metabolic Syndrome are the fastest growing health markets in the world and all can lead to MASH

 

20 Million

MASH affects up to 20 million people in the U.S., and is the leading indication for liver transplant…

75 Million

75 million of adults in the U.S. have MASLD

25 Million

>25% of US adults have MASLD, with 20% progressing to MASH

Source: Int J Mol Sci, 2019; www.liverfoundation.org; Clin Diabetes and Endocrinology, 2020

Facts & Prevalence
  • 5% of US adults with MASH
  • 30-60% of T2D patients have MASLD
  • 75% of overweight people have MASLD
  • 35% of MASH cases progress to liver fibrosis

Worldwide prevalence of MASLD is considerably higher than previously estimated and is continuing to increase at an alarming rate. The overall prevalence of MASLD worldwide is estimated to be 32.4%
(95% CI 29.9–34.9).

- Lancet, Gastroenterology & Hepatology, Sept 2022

Pipeline and Milestones for Next Generation NITs in MASLD, MASH, Liver Fibrosis, and Liver Cirrhosis

Other Tests: Key Facts

  • Liquid biopsy tests are gaining traction in the diagnostics industry as a viable alternative to traditional invasive procedures

  • Three non-specific diagnostic tests have been approved by the FDA: Siemens’ ELF Test (a 3 biomarker blood assay), EchoSens’ FibroScan (an ultrasound device), and Perspectum Diagnostics’ LiverMultiScan (an injectable imaging marker)

  • Other available NITs include: NIS4, OWLiver, FibroSURE, FIB-4, AGILE3+, LIVERFASt, and many others, but in large scale, multi-year studies such as LITMUS and NIMBLE, no biomarker has shown >0.9 AUROC.

Quick Links

Contact Us

Scroll to Top